BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zarogoulidis K, Eleftheriadou E, Kontakiotis T, Gerasimou G, Zarogoulidis P, Sapardanis I, Galaktidou G, Sakkas L, Gotzamani-Psarrakou A, Karatzas N. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. Lung Cancer 2012;76:84-8. [PMID: 22018594 DOI: 10.1016/j.lungcan.2011.09.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. Int J Mol Sci 2020;21:E1682. [PMID: 32121432 DOI: 10.3390/ijms21051682] [Cited by in Crossref: 26] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
2 Kosuda A, Shirahata T, Kudo N, Uehara Y, Miyawaki M, Hagiwara A, Murakami R, Shimizu K. Long-term Survival of a Patient with Small Cell Lung Cancer Secreting ADH and ACTH Simultaneously, Following the Prolonged Use of Amrubicin. Intern Med 2020;59:107-12. [PMID: 31511478 DOI: 10.2169/internalmedicine.2838-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer). Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. Lung Cancer 2019;134:121-6. [PMID: 31319970 DOI: 10.1016/j.lungcan.2019.06.011] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Lehman JM, Hoeksema MD, Staub J, Qian J, Harris B, Callison JC, Miao J, Shi C, Eisenberg R, Chen H, Chen SC, Massion PP. Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer. Int J Cancer 2019;144:1104-14. [PMID: 30152518 DOI: 10.1002/ijc.31771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
5 Cortellini A, Dal Mas A, Cannita K, Collina G, Parisi A, Pavese F, Porzio G, Verna L, Ficorella C. Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives. J Thorac Dis 2018;10:E520-5. [PMID: 30174924 DOI: 10.21037/jtd.2018.06.44] [Reference Citation Analysis]
6 Stumpf C, Kaemmerer D, Neubauer E, Sänger J, Schulz S, Lupp A. Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer. J Cancer Res Clin Oncol 2018;144:1921-32. [PMID: 30076481 DOI: 10.1007/s00432-018-2722-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sapalidis K, Zarogoulidis P, Pavlidis E, Laskou S, Katsaounis A, Koulouris C, Giannakidis D, Mantalovas S, Huang H, Bai C, Wen Y, Wang L, Sardeli C, Amaniti A, Karapantzos I, Karapantzou C, Hohenforst-Schmidt W, Konstantinou F, Kesisoglou I, Benhanseen N. Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination. J Cancer 2018;9:1973-7. [PMID: 29896282 DOI: 10.7150/jca.24782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Li J, Lu M, Lu Z, Li Z, Liu Y, Yang L, Li J, Zhang X, Zhou J, Wang X, Gong J, Gao J, Li Y, Shen L. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Oncotarget 2017;8:25669-78. [PMID: 27788498 DOI: 10.18632/oncotarget.12900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Tartarone A, Lerose R, Aieta M. Somatostatin Analog Therapy in Small Cell Lung Cancer. Semin Nucl Med 2016;46:239-42. [PMID: 27067504 DOI: 10.1053/j.semnuclmed.2015.12.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Hohenforst-Schmidt W, Zarogoulidis P, Steinheimer M, Benhassen N, Tsiouda T, Baka S, Yarmus L, Stratakos G, Organtzis J, Pataka A, Tsakiridis K, Karapantzos I, Karapantzou C, Darwiche K, Zissimopoulos A, Pitsiou G, Zarogoulidis K, Man YG, Rittger H. Tyrosine Kinase Inhibitors for the Elderly. J Cancer 2016;7:687-93. [PMID: 27076850 DOI: 10.7150/jca.14819] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
11 Hohenforst-Schmidt W, Zarogoulidis P, Pitsiou G, Linsmeier B, Tsavlis D, Kioumis I, Papadaki E, Freitag L, Tsiouda T, Turner JF, Browning R, Simoff M, Sachpekidis N, Tsakiridis K, Zaric B, Yarmus L, Baka S, Stratakos G, Rittger H. Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature. J Cancer 2016;7:377-90. [PMID: 26918052 DOI: 10.7150/jca.13611] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
12 Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther 2015;152:98-110. [PMID: 25956467 DOI: 10.1016/j.pharmthera.2015.05.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 9.6] [Reference Citation Analysis]
13 Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Lampaki S, Lazaridis G, Organtzis J, Kyriazis G, Hohenforst-Schmidt W, Tsirgogianni K, Karavasilis V, Baka S, Darwiche K, Freitag L, Trakada G, Zarogoulidis K. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC? J Cancer 2015;6:360-6. [PMID: 25767606 DOI: 10.7150/jca.11308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
14 Kaemmerer D, Specht E, Sänger J, Wirtz RM, Sayeg M, Schulz S, Lupp A. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab 2015;100:831-40. [PMID: 25494861 DOI: 10.1210/jc.2014-2699] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
15 Lewin J, Cullinane C, Akhurst T, Waldeck K, Watkins DN, Rao A, Eu P, Mileshkin L, Hicks RJ. Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. Eur J Nucl Med Mol Imaging 2015;42:25-32. [DOI: 10.1007/s00259-014-2888-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
16 Sollini M, Farioli D, Froio A, Chella A, Asti M, Boni R, Grassi E, Roncali M, Versari A, Erba PA. Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients. J Thorac Oncol 2013;8:1095-101. [PMID: 23857400 DOI: 10.1097/JTO.0b013e318293f051] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
17 Tartarone A, Lerose R, Ardito R, Troiani L, Tedesco B, Bozza G, Cangiano R, Aieta M. Long-term survival in small cell lung cancer: a case report and review of the literature. Future Oncology 2014;10:523-8. [DOI: 10.2217/fon.13.213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
18 Zarogoulidis P, Darwiche K, Hohenforst-Schmidt W, Huang H, Li Q, Freitag L, Zarogoulidis K. Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer. Future Oncol 2013;9:1171-94. [PMID: 23902248 DOI: 10.2217/fon.13.67] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
19 Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H, Simoff M, Li Q, Browning R, Turner FJ, Le Pivert P, Spyratos D, Zarogoulidis K, Celikoglu SI, Celikoglu F, Brachmann J. Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Devel Ther 2013;7:571-83. [PMID: 23898222 DOI: 10.2147/DDDT.S46393] [Cited by in Crossref: 7] [Cited by in F6Publishing: 30] [Article Influence: 0.8] [Reference Citation Analysis]
20 Zarogoulidis P, Hohenforst-Schmidt W, Darwiche K, Krauss L, Sparopoulou D, Sakkas L, Gschwendtner A, Huang H, Turner FJ, Freitag L, Zarogoulidis K. 2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy. Gene Ther 2013;20:1022-8. [PMID: 23719068 DOI: 10.1038/gt.2013.27] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
21 Keskin O, Yalcin S. A review of the use of somatostatin analogs in oncology. Oncotargets Ther. 2013;6:471-483. [PMID: 23667314 DOI: 10.2147/ott.s39987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
22 Zarogouldis P, Karamanos NK, Porpodis K, Domvri K, Huang H, Hohenforst-Schimdt W, Goldberg EP, Zarogoulidis K. Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology. Int J Mol Sci 2012;13:10828-62. [PMID: 23109824 DOI: 10.3390/ijms130910828] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]